Savient Pharmaceuticals (SVNTQ) Stock Price, News & Analysis

Company Overview

Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on identifying, developing and commercializing novel therapies for patients with severe gout and other inflammatory and rare disorders. Headquartered in East Brunswick, New Jersey, Savient was formed through the renaming of BioSeq, Inc. and has concentrated its efforts on advancing recombinant enzyme–based treatments to address significant unmet medical needs.

The company’s lead product, KRYSTEXXA® (pegloticase), is a first‐in‐class, FDA‐approved enzyme therapy indicated for chronic gout in adult patients refractory to conventional therapies. KRYSTEXXA is administered via intravenous infusion and works by catalyzing the oxidation of uric acid into a more soluble compound, thereby rapidly lowering serum uric acid levels and reducing the risk of gout flares, tophus development and joint damage. Savient has also pursued collaborations and licensing arrangements to explore KRYSTEXXA’s potential in additional indications and geographies.

Savient’s commercial efforts have primarily targeted the United States, with strategic partnerships in Europe and other territories to facilitate wider access to its therapies. The company has leveraged a focused sales force, medical affairs team and reimbursement specialists to support patient access programs, education initiatives and physician outreach. Through these efforts, Savient aims to improve quality of life for patients suffering from severe, treatment‐resistant gout and related conditions.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: 340,036 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Industrials
• Industry: Medicinal Chemicals
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:SVNTQ
• Previous Symbol: NASDAQ:SVNT
• CIK: 722104
• Web: www.savientpharma.com
• Phone: +1-732-4189300
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A